Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis - Top-Institutions - MDSpire

Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis

  • By

  • Onur Baş

  • Bediz Kurt İnci

  • İmdat Eroğlu

  • Safa Can Efil

  • Seher Kaya

  • Pınar Kubilay Tolunay

  • Taha Koray Şahin

  • Cengiz Karaçin

  • Ozan Yazıcı

  • Mehmet Ali Nahit Şendur

  • Berna Ömür Çakmak Öksüzoğlu

  • Sercan Aksoy

  • November 28, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Breast Cancer Research
    • Pharmacology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Hepatology
    • Breast Cancer

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Translational Research
    • Breast Cancer

  • #4

    Hacettepe University Hospital
    Hacettepe University Hospital

    Ankara, Turkey

    Key Differentiators

    • Medical Oncology
    • Breast Cancer
    • Clinical Pharmacology

  • #5

    Gazi University Hospital
    Gazi University Hospital

    Ankara, Turkey

    Key Differentiators

    • Medical Oncology
    • Breast Cancer
    • Clinical Research

Original Source(s)

Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis

  • by Onur Baş, Bediz Kurt İnci, İmdat Eroğlu, Safa Can Efil, Seher Kaya, Pınar Kubilay Tolunay, Taha Koray Şahin, Cengiz Karaçin, Ozan Yazıcı, Mehmet Ali Nahit Şendur, Berna Ömür Çakmak Öksüzoğlu, Sercan Aksoy

  • November 28, 2025

Related Content

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Synthetic short RNA in cancer